Treatment of head and neck squamous cell carcinoma (HNSCC) requires combined modalities of surgery, radiation and cytotoxic chemotherapy as well as targeted anti-epidermal growth factor receptor (EGFR) agents and most recently, immunotherapies that inhibit the PD1-PD-L1 axis. Here, CD274 is linked to head and neck squamous cell carcinoma.